Camfil Farr changes name back to Camfil

Camfil Farr changes name back to Camfil

NEWS/EXCHANGE RATES Freudenberg expands in China with new filter plant Camfil Farr changes name back to Camfil F reudenberg has opened a new CNY36...

66KB Sizes 0 Downloads 141 Views

NEWS/EXCHANGE RATES

Freudenberg expands in China with new filter plant

Camfil Farr changes name back to Camfil

F

reudenberg has opened a new CNY36 million production facility in Chengdu, Sichuan Province to serve the growing demand for automotive filters in Western China. Freudenberg Vilene Filter (Chengdu) Co Ltd, a joint venture between Freudenberg Filtration Technologies and Japan Vilene Co Ltd, will produce engine air intake filters and cabin air filters for the Chinese automotive industry and serve as a logistics and service centre for industrial filtration components and systems. The 12 000 sq m manufacturing site is situated at Xindu Industrial Park in Chengdu. Sixty employees will be working at the new site by the end of 2013. “This is an important step. Together we will deliver state-of-the-art filtration technology to the growing automotive industry in Chengdu with companies like Volkswagen and Geely Volvo,” said Dr Joerg Sievert, a member of the Freudenberg Filtration Technologies management board and chairman of the Freudenberg Filter China board. The project took seven months from the ground breaking to the start of production. Freudenberg Filtration Technologies already has plants in Changchun and Suzhou, China.”

S

For further information, visit www.freudenberg-filter. com and www.vilene.co.jp

For further information, visit www.camfil.com and www.camfilapc.com

wedish air filtration specialist Camfil Farr is changing its official name back to Camfil, as the company celebrates its 50th anniversary. The air filtration specialist adopted the Camfil Farr name following Camfil’s acquisition of Farr Co in 2000. The company says that the Camfil name is now well known in the US and throughout the world and that the time is right, particularly with its 50th anniversary approaching, to go back to the original Camfil name. Camfil Farr Air Pollution Control, a producer of dust and fume collectors, is now operating under the name Camfil Air Pollution Control. Customers will continue to see the Farr name and logo on the Farr Gold Series dust collector. The Camfil group, headquartered in Stockholm, Sweden, has 3484 employees and sales of around SEK4.9 billion. International markets account for almost 90% of sales. Founded in 1963 as a joint venture between Luftkonditionering and Cambridge Air Filter Co, today Camfil has a worldwide network of state-of-the-art R&D facilities, including a newly opened research centre in Trosa, Sweden.

Exchange Rates against the US Dollar Date: 19.3.2013 Country Australia

Rate A$0.96

Country Netherlands

Austria

E0.78

Norway

Belgium

E0.78

Philippines

C$1.00

Singapore

Canada

Rate E0.78 NOK5.84 Peso40.74 S$1.25

China

CNY6.21

South Africa

R9.24

Denmark

DKK5.78

South Korea

KWn1115.52

Finland

E0.78

Spain

France

E0.78

Sweden

SEK6.45

Germany

E0.78

Switzerland

CHF0.95

Taiwan

T$29.77

Thailand

Bt29.20

India Italy

Rs54.38 E0.78

Japan

¥95.30

UK

Malaysia

Rt3.12

USA

16

Filtration Industry Analyst

E0.78

£0.66

Editorial Office: Elsevier Limited The Boulevard, Langford Lane Kidlington Oxford OX5 1GB United Kingdom Tel: +44 (0) 1865 843695 Fax: +44 (0) 1865 843973 Web: www.filtrationindustryanalyst.com Editor: Roisin Reidy E-mail: [email protected] Production Support Manager: Lin Lucas E-mail: [email protected] Publisher: David Hopwood Subscription Information An annual subscription to Filtration Industry Analyst includes 12 issues and online access for up to 5 users. Prices: 1291 for all European countries & Iran US$1448 for all countries except Europe and Japan ¥171 700 for Japan (Prices valid until 31 December 2013) To subscribe send payment to the address above. Tel: +44 (0)1865 843687 or via www.filtrationindustryanalyst.com Subscriptions run for 12 months, from the date payment is received. Permissions may be sought directly from Elsevier Global Rights Department, PO Box 800, Oxford OX5 1DX, UK; phone: +44 1865 843830, fax: +44 1865 853333, email: [email protected]. You may also contact Global Rights directly through Elsevier’s home page (www.elsevier.com), selecting first ‘Support & contact’, then ‘Copyright & permission’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: +1 978 750 8400, fax: +1 978 750 4744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: +44 (0)20 7631 5555; fax: +44 (0)20 7631 5500. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution. Permission of the Publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the Publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher. Address permissions requests to: Elsevier Science Global Rights Department, at the mail, fax and email addresses noted above. Notice No responsibility is assumed by the Publisher for any injury and/ or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

Digitally Produced by Mayfield Press (Oxford) LImited 12976

US$1.00

March 2013